CN104273546A - Zinc-iron folic acid tablet formula - Google Patents
Zinc-iron folic acid tablet formula Download PDFInfo
- Publication number
- CN104273546A CN104273546A CN201410557353.1A CN201410557353A CN104273546A CN 104273546 A CN104273546 A CN 104273546A CN 201410557353 A CN201410557353 A CN 201410557353A CN 104273546 A CN104273546 A CN 104273546A
- Authority
- CN
- China
- Prior art keywords
- folic acid
- zinc
- iron
- gluconate
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 title claims abstract description 62
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 title claims abstract description 31
- 229960000304 folic acid Drugs 0.000 title claims abstract description 31
- 235000019152 folic acid Nutrition 0.000 title claims abstract description 31
- 239000011724 folic acid Substances 0.000 title claims abstract description 31
- KFZAUHNPPZCSCR-UHFFFAOYSA-N iron zinc Chemical compound [Fe].[Zn] KFZAUHNPPZCSCR-UHFFFAOYSA-N 0.000 title claims abstract description 14
- 239000007916 tablet composition Substances 0.000 title abstract 3
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims abstract description 13
- 239000004222 ferrous gluconate Substances 0.000 claims abstract description 13
- 235000013924 ferrous gluconate Nutrition 0.000 claims abstract description 13
- 229960001645 ferrous gluconate Drugs 0.000 claims abstract description 13
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 claims abstract description 13
- 235000011478 zinc gluconate Nutrition 0.000 claims abstract description 13
- 239000011670 zinc gluconate Substances 0.000 claims abstract description 13
- 229960000306 zinc gluconate Drugs 0.000 claims abstract description 13
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 11
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 11
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 11
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 11
- 235000019156 vitamin B Nutrition 0.000 claims abstract description 11
- 239000011720 vitamin B Substances 0.000 claims abstract description 11
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229920003081 Povidone K 30 Polymers 0.000 claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims description 11
- 229930003270 Vitamin B Natural products 0.000 claims description 10
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 6
- 235000015097 nutrients Nutrition 0.000 abstract description 5
- 235000005911 diet Nutrition 0.000 abstract description 3
- 230000000378 dietary effect Effects 0.000 abstract description 3
- 235000016709 nutrition Nutrition 0.000 abstract description 3
- 230000035764 nutrition Effects 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
- 235000019359 magnesium stearate Nutrition 0.000 abstract 1
- 230000001502 supplementing effect Effects 0.000 abstract 1
- 229940046001 vitamin b complex Drugs 0.000 abstract 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 14
- 229910052742 iron Inorganic materials 0.000 description 7
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 5
- 239000011701 zinc Substances 0.000 description 5
- 229910052725 zinc Inorganic materials 0.000 description 5
- 239000003826 tablet Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000008821 health effect Effects 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 102000008857 Ferritin Human genes 0.000 description 2
- 108050000784 Ferritin Proteins 0.000 description 2
- 238000008416 Ferritin Methods 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 102000002070 Transferrins Human genes 0.000 description 2
- 108010015865 Transferrins Proteins 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010028034 Mouth ulceration Diseases 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 208000007642 Vitamin B Deficiency Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229910001447 ferric ion Inorganic materials 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000021332 multicellular organism growth Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 229940100691 oral capsule Drugs 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000014860 sensory perception of taste Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a zinc-iron folic acid tablet formula. According to the formula, components in percentage by weight are as follows: 65.75-68.70% of microcrystalline cellulose, 6.7-8.7% of ferrous gluconate, 22.5-24.5% of zinc gluconate, 1.00-3.00% of PVP-K30, 0.5-1.5% of magnesium stearate, 0.01-0.03% of folic acid and 0.03-0.08% of vitamin B complex. The zinc-iron folic acid tablet formula disclosed by the invention can be combined with dietary nutrition structure of people and can integrate the effects of several nutrient elements on human health and can combine the physiological characteristics, thereby being safe and effective, scientific and reasonable and being capable of supplementing formulas such as folic acid, ferrous gluconate and zinc gluconate at the same time.
Description
Technical field
The present invention relates to a kind of iron zinc Couteat of Folic Acid formula.
Background technology
Blood is the source maintaining human life, iron and folic acid are then the not replaceable important nutrient of tonic blood, and zinc also plays an important role to human body growth, iron and folic acid are combined, addition element zinc in addition, disposable supplementary anaemia of different nature, and promote the growth and development of human body.Also a lot of iron zinc Couteat of Folic Acid is had on the market at present, but the space also having needs perfect in component ratio, not scientific and reasonable.
Summary of the invention
For above-mentioned Problems existing, the invention provides a kind of iron zinc Couteat of Folic Acid formula; In conjunction with our dietary nutrition structure, comprehensive several nutrient is to the health effect of people and in conjunction with its physilogical characteristics, safe and effective, scientific and reasonable, and the formula such as folic acid, ferrous gluconate, zinc gluconate supplements simultaneously.
In order to achieve the above object, the technical solution adopted in the present invention is as follows:
A kind of iron zinc Couteat of Folic Acid formula, contained composition and weight ratio as follows: microcrystalline cellulose 65.75-68.70 %, ferrous gluconate 6.7-8.7%, zinc gluconate 22.5-24.5 %, PVP-K30 1.00-3.00%, dolomol 0.5-1.5%, folic acid 0.01-0.03%, vitamin B compound 0.03-0.08%.
Further, contained composition and weight ratio as follows: microcrystalline cellulose 65.70%, ferrous gluconate 7.7%, zinc gluconate 23.5%, PVP-K30 2.00%, dolomol 1%, folic acid 0.02%, vitamin B compound 0.08%.
Its basic technology is: folic acid, vitamin B compound and microcrystalline cellulose equal increments, guarantee the homogeneity of every sheet iron zinc Couteat of Folic Acid medium trace element, adopt advanced one-step palletizing technology, greatly shorten product granulation required personnel man-hour, advanced bilateral charging tablet machine, has saved compressing tablet man-hours requirement greatly.
beneficial effect of the present invention:
Microcrystalline cellulose is widely used in pharmaceutical preparation, mainly in oral tablet and capsule, is used as diluent and adhesive, not only can be used for wet granulation and also can be used for dry method direct tablet compressing.Also have certain lubrication and calving disaggregation, iron is the element of needed by human, is the necessary material manufacturing hemoglobin.Ferrous gluconate absorptivity is high, after it enters blood, is oxidized to ferric ion at once, and transferrins is combined in blood plasma, becomes blood plasma iron, and be that carrier transport is to liver with transferrins, spleen, the tissues such as bone, store with ferritin form, in bone, the iron of ferritin can be combined into hemoglobin, in skeletal muscle, become myoglobins, when iron deficiency, plasma iron transport rate increases, absorptivity is also accelerated, and iron uptake is increased.
Zinc has enhancing development, improves the effect of the sense of taste; Zinc gluconate is zinc tonic, is mainly used in baby and old age, the growth retardation that gravid woman causes because lacking zinc, malnutritive, apositia, recurrent oral ulceration, the diseases such as skin acne.
PVP-K30 is a kind of non-ionic macromolecule compound, is most characteristic in N vinylamide polymer, and obtains extensive use with its excellent unique performance.Dolomol is used as glidant in direct tablet compressing.
Folic acid be participate in DNA and RNA synthesis important coenzyme, be cell division, grow indispensable vitamin, all grow or metabolism vigorous organizing all need enough folic acid supplies.
Vitamin B compound can be used for malnutrition, poor appetite, acne, pregnant woman, nursing women and heating and the treatment of the various diseases of the Vitamin B deficiency caused
The comprehensive several nutrient of iron zinc Couteat of Folic Acid of the present invention is to the health effect of people and in conjunction with its physilogical characteristics, safe and effective.
Detailed description of the invention
Below in conjunction with specific embodiment, technical scheme of the present invention is further described.
A kind of iron zinc Couteat of Folic Acid formula, contained composition and weight ratio as follows: microcrystalline cellulose 65.75-68.70 %, ferrous gluconate 6.7-8.7%, zinc gluconate 22.5-24.5 %, PVP-K30 1.00-3.00%, dolomol 0.5-1.5%, folic acid 0.01-0.03%, vitamin B compound 0.03-0.08%.
Embodiment 1
Microcrystalline cellulose 63.70-66.70 %, ferrous gluconate 6.7%, zinc gluconate 22.5 %, PVP-K30 1.00%, dolomol 0.5%, folic acid 0.01%, vitamin B compound 0.03%.
Embodiment 2
A kind of iron zinc Couteat of Folic Acid formula, contained composition and weight ratio as follows: microcrystalline cellulose 65.75%, ferrous gluconate 7.7%, zinc gluconate 23.5%, PVP-K30 2.00%, dolomol 1%, folic acid 0.02%, vitamin B compound 0.08%.
Embodiment 3
Microcrystalline cellulose 66.70 %, ferrous gluconate 8.01%, zinc gluconate 22.7 %, PVP-K30 1.50%, dolomol 1.01%, folic acid 0.03%, vitamin B compound 0.05%.
The present embodiment can in conjunction with our dietary nutrition structure, and comprehensive several nutrient is to the health effect of people and in conjunction with its physilogical characteristics, safe and effective, scientific and reasonable, and the formula such as folic acid, ferrous gluconate, zinc gluconate supplements simultaneously.
The foregoing is only the preferred embodiments of the present invention; those of ordinary skill in the art it is to be appreciated that above-described embodiment is not as limitation of the invention; every various equivalent transformations utilizing description of the present invention to do, all within protection scope of the present invention.
Claims (2)
1. an iron zinc Couteat of Folic Acid formula, it is characterized in that: contained composition and weight ratio as follows: microcrystalline cellulose 65.75-68.70 %, ferrous gluconate 6.7-8.7%, zinc gluconate 22.5-24.5 %, PVP-K30 1.00-3.00%, dolomol 0.5-1.5%, folic acid 0.01-0.03%, vitamin B compound 0.03-0.08%.
2. a kind of iron zinc Couteat of Folic Acid formula according to claim 1, it is characterized in that: contained composition and weight ratio as follows: microcrystalline cellulose 65.70%, ferrous gluconate 7.7%, zinc gluconate 23.5%, PVP-K30 2.00%, dolomol 1%, folic acid 0.02%, vitamin B compound 0.08%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410557353.1A CN104273546A (en) | 2014-10-21 | 2014-10-21 | Zinc-iron folic acid tablet formula |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410557353.1A CN104273546A (en) | 2014-10-21 | 2014-10-21 | Zinc-iron folic acid tablet formula |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104273546A true CN104273546A (en) | 2015-01-14 |
Family
ID=52249285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410557353.1A Pending CN104273546A (en) | 2014-10-21 | 2014-10-21 | Zinc-iron folic acid tablet formula |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104273546A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001024642A1 (en) * | 1999-10-07 | 2001-04-12 | Snowden Robert B | Nutritional composition for treating inflammatory bowel diseases |
| CN102006868A (en) * | 2008-04-18 | 2011-04-06 | 博科药物化学有限公司 | Iron and zinc based pharmaceutical formulation for iron deficiency treatment |
| CN103432161A (en) * | 2013-08-13 | 2013-12-11 | 深圳市麦金利实业有限公司 | Multivitamin mineral effervescent tablet and preparation method thereof |
-
2014
- 2014-10-21 CN CN201410557353.1A patent/CN104273546A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001024642A1 (en) * | 1999-10-07 | 2001-04-12 | Snowden Robert B | Nutritional composition for treating inflammatory bowel diseases |
| CN102006868A (en) * | 2008-04-18 | 2011-04-06 | 博科药物化学有限公司 | Iron and zinc based pharmaceutical formulation for iron deficiency treatment |
| CN103432161A (en) * | 2013-08-13 | 2013-12-11 | 深圳市麦金利实业有限公司 | Multivitamin mineral effervescent tablet and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105410943B (en) | A kind of multivitamin tablet and preparation method thereof | |
| CN103263018A (en) | Nitric oxide functional beverage and preparation method thereof | |
| CN103656627A (en) | Vitamin C collagen compound effervescent tablet and preparation method thereof | |
| CN104605334A (en) | Cordyceps sinensis oral tablet and preparation method thereof | |
| CN104705642A (en) | Cordyceps militaris oral tablet and preparation method thereof | |
| CN101253984A (en) | Royal jelly ginkgo leaf nutrition health products and method of preparing the same | |
| CN104273546A (en) | Zinc-iron folic acid tablet formula | |
| CN107889889A (en) | A kind of formula for the Astaxanthin In Haematococcus Pluvialis milk powder for contributing to recovery of parturient | |
| CN105767997A (en) | Bee pollen and preparation method thereof | |
| CN106666534B (en) | Children fruit and vegetable superfine powder chewable tablets and preparation method thereof | |
| CN104857179A (en) | Traditional Chinese medicine composition capable of improving nutritional anemia | |
| CN101204224A (en) | Antler processing method | |
| CN103653105A (en) | Method for preparing health-care tremella beverage | |
| CN104206827A (en) | Fish feed additive | |
| CN105878277A (en) | Oral vitamin capsules for promoting hair growth and beautifying hair | |
| US20070031487A1 (en) | Nutritional supplement for women | |
| CN106619755A (en) | Preparation method and preparation of natural moringa oleifera folic acid | |
| CN101258935A (en) | Health-care spirulina food | |
| CN111778129A (en) | Nucleic acid and amino acid health oral liquid and preparation method thereof | |
| CN105853350A (en) | Genistein solution, preparation method and application | |
| Van Schoor | The value of supplements | |
| CN117297101A (en) | Composite nutritional supplement, preparation method and application thereof | |
| CN116784479A (en) | Homocysteine-reducing B-vitamin tablet | |
| CN104056036A (en) | Health care composition capable of whitening and removing freckle | |
| CN104116081A (en) | Phyllanthus emblica SOD (Superoxide Dismutase) health food additive |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150114 |